CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway
Publication date: Available online 11 February 2021Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Fang Yang, Shuai Zhang, Qingwei Meng, Fengrui Zhou, Bo Pan, Fang Liu, Yan Yu
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Men | Non-Small Cell Lung Cancer | Respiratory Medicine